Evidence map›Paper›PMID 41954343›Full record

ArticlePathologica2025

Distinction of thymic carcinoma and type B3 thymoma using ancillary biomarkers.

Anello Marcello Poma, Alessandra Celi, Vittorio Aprile, Iacopo Petrini, Stefano Stanca, Diana Bacchin, Cristina Niccoli, Melania Guida, Michelangelo Maestri, Marcello Carlo Ambrogi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anello Marcello PomaDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Alessandra CeliDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Vittorio AprileDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Iacopo PetriniDepartment of Translational Research and New Technologies in Surgery and Medicine, University of Pisa, Pisa, Italy.
Stefano StancaDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Diana BacchinDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Cristina NiccoliUnit of Surgical Pathology, University Hospital of Pisa, Pisa, Italy.
Melania GuidaUnit of Neurology, University Hospital of Pisa, Pisa, Italy.
Michelangelo MaestriUnit of Neurology, University Hospital of Pisa, Pisa, Italy.
Marcello Carlo AmbrogiDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Marco LucchiDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Greta AlìDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Thymic carcinomas (TC) are rare and understudied tumors. Pitfalls exist with TC diagnosis, and biomarkers are needed to support the pathologist. Here, we tested a series of biomarkers to differentiate TC from type B3 thymoma. Methods: A consecutive series of 48 patients, 26 with TC and 22 with type B3 thymoma entered the study. Immunohistochemical expression of CD5, CD117, BAP1, MTAP, Ki-67 was evaluated. CDKN2A status was assessed by FISH. Results: CD5 and CD117 were expressed in TC only (n = 19 and n = 20 respectively). Five TC did not show CD5 or CD117 expression. BAP1 expression was lost in 3 TC, while MTAP staining was absent in 3 TC and 1 type B3 thymoma. Conclusions: CD5 and CD117 are the best markers for TC. While the addition of other markers (i.e., BAP1 loss, MTAP loss and CDKN2A deletion) might be useful in cases negative for CD5 and CD117, rare cases of type B3 thymoma might harbor these alterations.

Indexed as

Biomarkers, TumorThymomaThymus NeoplasmsAdultAgedAged, 80 and overCD5 AntigensCyclin-Dependent Kinase Inhibitor p16Diagnosis, DifferentialFemaleHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMaleMiddle AgedProto-Oncogene Proteins c-kitBiomarkers, TumorCD5 AntigensCyclin-Dependent Kinase Inhibitor p16Proto-Oncogene Proteins c-kitTumor Suppressor ProteinsUbiquitin ThiolesterasebiomarkersdiagnosisIHCthymic carcinomatype B3 thymoma

Identifiers

PMID41954343
PMCPMC13094316

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.